• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Pharmacokinetics of metronidazole and its major metabolite after a high intravenous dose.

作者信息

Bergan T, Aase S, Leinebo O, Harbitz T, Olsen A, Liavag I

出版信息

Scand J Gastroenterol Suppl. 1984;91:113-23.

PMID:6588488
Abstract

The pharmacokinetics of metronidazole (M) and hydroxy-metronidazole (OH-M) were determined in 8 healthy volunteers after a single dose of 1.5 g metronidazole given as an intravenous infusion during 50 min. High-pressure liquid chromatography was used for the assays. The serum concentration determined 1 h after the start of infusion was 40.21 +/- 6.54 mg/1. The peak concentrations of the metabolite were observed after 8-12 h. The serum concentrations of M and OH-M were detectable throughout the 48 h monitored. The serum half-life of M was 7.6 h and of OH-M 13.3 h. The terminal phase distribution volume was 43.2 lit and the total body clearance 4.0 lit./h. The prophylactic use of 1.5 g of metronidazole given as a single intravenous dose 1 h prior to surgery is supported by the pharmacokinetic assessments in this study.

摘要

相似文献

1
Pharmacokinetics of metronidazole and its major metabolite after a high intravenous dose.
Scand J Gastroenterol Suppl. 1984;91:113-23.
2
Pharmacokinetics and bioavailability of metronidazole after tablets, suppositories and intravenous administration.甲硝唑片剂、栓剂及静脉给药后的药代动力学和生物利用度。
Scand J Gastroenterol Suppl. 1984;91:45-60.
3
Pharmacokinetics of intravenous metronidazole at different dosages in healthy subjects.
Int J Clin Pharmacol Ther Toxicol. 1991 Oct;29(10):386-90.
4
Pharmacokinetics of metronidazole and its metabolites in reduced renal function.甲硝唑及其代谢产物在肾功能减退患者中的药代动力学。
Chemotherapy. 1986;32(4):305-18. doi: 10.1159/000238429.
5
Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole.不同剂量静脉注射甲硝唑的群体药代动力学建模与蒙特卡洛模拟
Diagn Microbiol Infect Dis. 2006 Aug;55(4):303-9. doi: 10.1016/j.diagmicrobio.2006.06.013.
6
Pharmacokinetics of metronidazole given to horses by intravenous and oral routes.
Am J Vet Res. 1986 Aug;47(8):1726-9.
7
Pharmacokinetics of metronidazole and its concentration in body fluids and endometrial tissues of mares.甲硝唑在母马体液和子宫内膜组织中的药代动力学及其浓度
Am J Vet Res. 1992 Oct;53(10):1807-12.
8
Serum and tissue pharmacokinetics of intravenous metronidazole in surgical patients.
Acta Chir Scand. 1989 Jun-Jul;155(6-7):347-50.
9
Comparative pharmacokinetics of metronidazole and tinidazole used as single dose prophylactic agents.甲硝唑和替硝唑作为单剂量预防剂的比较药代动力学
Scand J Gastroenterol Suppl. 1984;90:97-106.
10
Plasma and skin blister fluid concentrations of metronidazole and its hydroxy metabolite after oral administration.口服给药后甲硝唑及其羟基代谢物的血浆和皮肤水疱液浓度。
Pol J Pharmacol. 1996 Jan-Feb;48(1):47-52.

引用本文的文献

1
Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects.750毫克静脉注射左氧氟沙星与不同剂量甲硝唑在健康成年受试者中的药代动力学和药效学。
Antimicrob Agents Chemother. 2004 Dec;48(12):4597-605. doi: 10.1128/AAC.48.12.4597-4605.2004.
2
Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials.硝基咪唑类抗菌药物的药代动力学和药效学
Clin Pharmacokinet. 1999 May;36(5):353-73. doi: 10.2165/00003088-199936050-00004.
3
Prophylactic regimens in colorectal surgery: an open, randomized, consecutive trial on metronidazole used alone or in combination with ampicillin or doxycycline.
结直肠手术中的预防性用药方案:一项关于单独使用甲硝唑或联合氨苄西林或强力霉素的开放性、随机、连续试验。
World J Surg. 1986 Dec;10(6):1003-8. doi: 10.1007/BF01658658.
4
Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives.甲硝唑及其他硝基咪唑类抗感染药物的临床药代动力学
Clin Pharmacokinet. 1992 Nov;23(5):328-64. doi: 10.2165/00003088-199223050-00002.